A study on the incidence and severity of hand-footsyndrome in cancer patients treated with capecitabine

AUTHOR(s) : Mahanta Neelakshi, Kutum Niharika, Ali AS, Kalita NK, Deka Hitesh, Lokkur PK
DOI No. : 10.31741/ijhrmlp.v6.i2.2020.4


Introduction: Hand-Foot Syndrome is a localised dermatologic reaction and is one of the most common adverse effects of capecitabine containing chemotherapy in cancer patients. Although it is not life-threatening toxicity, it can be quite serious, leading to a delay in or discontinuation of anticancer therapy. Objectives: To estimate the incidence of Hand-Foot Syndrome receiving treatment with capecitabine containing chemotherapy at State Cancer Institute and to determine the severity of Hand-Foot Syndrome. Materials and methods: The study was a hospital-based retrospective study conducted at a State Cancer Institute in Assam, for a period of six months from August 2019 to January 2020. A total of fifty-one cancer patients were included, out of which thirty-three had Hand-Foot Syndrome. Results: Overall incidence of Hand-Foot Syndrome was 64.7% cases, 39.4%of cases in males and 60.6% cases in females. As per NCI-CTCAE grading, 60.6% of cases had grade 1 HFS, 36.4%of cases had grade 2 and 3% of cases had grade 3 HFS. The first episode of HFS occurred in 12.1% cases after cycle 1,60.6% cases after cycle 2 and 27.3% cases after cycle 3. Conclusion: The incidence of HFS is common in patients treated with capecitabine and usually starts within the first two cycles of therapy. It has a significant influence on patients quality of life and abilities.

Keywords: NCI-CTCAE; monotherapy; combination therapy.

Registered Office Address:
House No: One, Karmabir Bordoloi Path, Wireless,
Rukmini Nagar, Dispur-06, Assam, India

Mobile: 09435017802
Email: editor@ijhrmlp.org
Website: www.ijhrmlp.org
IJHRMLP is an open-access journal, and the articles published are instantly available to read and use again. The published articles thus can be downloaded, shared, and reused without restriction if the contributing original authors are appropriately cited. Author(s) retain the copyright of their article, with articles licensed to AHRME and the journal following the Creative Commons Attribution License (CC-BY).
Maintain By Prism Infosys